|Bid||33.280 x 1100|
|Ask||33.290 x 8900|
|Day's Range||33.250 - 33.450|
|52 Week Range||29.830 - 35.380|
|PE Ratio (TTM)||28.08|
|Dividend & Yield||1.28 (3.84%)|
|1y Target Est||N/A|
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.
Apart from Pfizer’s (PFE) product developments, let's take a look at some recent pipeline and corporate developments.